Speciality: Hematology
Description:
A warm welcome to all the medical professionals in this crucial session asking the question: Should We Use DARA Up Front As First-Line Therapy in MM? The treatment landscape for multiple myeloma (MM) is rapidly evolving, and the introduction of powerful monoclonal antibodies like daratumumab (DARA) has fundamentally changed how we approach therapy. The core question now is whether to integrate DARA into the very first line of treatment for newly diagnosed multiple myeloma (NDMM) patients, and what the evidence says about this strategy.
The shift toward using DARA as part of frontline therapy is supported by robust clinical trial data. Studies such as the MAIA trial (for transplant-ineligible patients) and the GRIFFIN trial (for transplant-eligible patients) have demonstrated that adding DARA to standard regimens significantly improves the depth of response, including higher rates of complete remission and, crucially, minimal residual disease (MRD) negativity. Achieving MRD negativity is a powerful predictor of long-term, progression-free survival, and the use of DARA upfront has been shown to increase the chances of reaching this deep state of remission.
Therefore, get an overall knowledge of the evidence supporting the use of daratumumab as a frontline therapy in multiple myeloma. Listen to the webinar, grab the shared knowledge on this practice-changing data, and follow Hidoc for more such indispensable sessions that are driving oncology forward.
See More Webinars @ Hidoc Webinars
1.
Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.
2.
Study identifies new approach to protect the brain during radiation therapy
3.
While most cancer screenings won't prolong lives, there are still good reasons to continue screening.
4.
Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.
5.
Radiation therapy for patients with breast cancer
1.
Radiation in Oncology: Advances, Applications, and Accessibility
2.
The Next Generation of Precision: How Multi-Specific Antibodies are Redefining Oncology's Future - A 2025 Review
3.
Cracking Oncology Drug Resistance: New Strategies to Overcome Challenges in Modern Cancer Therapy
4.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
5.
Precision Oncology: Personalized Medicine Shaping the Future of Cancer Care
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
3.
Navigating the Complexities of Ph Negative ALL - Part XIII
4.
Navigating the Complexities of Ph Negative ALL - Part IV
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation